Jones Financial Companies Lllp grew its holdings in GSK plc (NYSE:GSK - Free Report) by 28.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,435 shares of the pharmaceutical company's stock after purchasing an additional 16,185 shares during the period. Jones Financial Companies Lllp's holdings in GSK were worth $2,450,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. SRS Capital Advisors Inc. lifted its position in GSK by 51.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,414 shares of the pharmaceutical company's stock worth $48,000 after buying an additional 480 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of GSK by 65.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 11,946 shares of the pharmaceutical company's stock valued at $402,000 after acquiring an additional 4,746 shares in the last quarter. Cape Investment Advisory Inc. raised its holdings in shares of GSK by 12.8% during the fourth quarter. Cape Investment Advisory Inc. now owns 7,184 shares of the pharmaceutical company's stock worth $243,000 after acquiring an additional 818 shares in the last quarter. Jacobi Capital Management LLC boosted its position in GSK by 3.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after purchasing an additional 389 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock valued at $637,061,000 after purchasing an additional 259,867 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.
GSK has been the topic of several research reports. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.25.
View Our Latest Analysis on GSK
Shares of GSK stock opened at $38.79 on Thursday. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.92. The stock has a market capitalization of $80.38 billion, a P/E ratio of 24.39, a PEG ratio of 1.12 and a beta of 0.58. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock has a 50 day moving average price of $35.25 and a two-hundred day moving average price of $37.20.
GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts expect that GSK plc will post 4.14 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.05%. GSK's payout ratio is presently 98.74%.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.